

**Supplementary Table 2.** Performance of XGBoost for predicting DAA treatment response in the overall cases

Predictive risk coefficient	Actual Non-SVR	Actual SVR	Accuracy	Sensitivity	Specificity	PPV	NPV
<b>Cutoff=0.5</b>							
≤0.5	Non-SVR 375 (69.7%)	10 (0.03%)	99.5%	69.7%	99.9%	97.4%	99.5%
>0.5	SVR 163 (30.3%)	33,753 (99.97%)					
<b>Cutoff=0.8</b>							
≤0.8	Non-SVR 385 (71.6%)	32 (0.1%)	99.5%	71.6%	99.9%	92.3%	99.5%
>0.8	SVR 153 (28.4%)	33,731 (99.9%)					
<b>Cutoff=0.9</b>							
≤0.9	Non-SVR 394 (73.2%)	80 (0.2%)	99.3%	73.2%	99.8%	83.1%	99.6%
>0.9	SVR 144 (26.8%)	33,683 (99.8%)					

XGBoost, eXtreme Gradient Boosting; DAA, direct-acting antivirals; SVR, sustained virological response; PPV, positive predictive value; NPV, negative predictive value.